Donate

Blog List

Update: Rebuttal to the 2018 ACG Crohn’s Disease Guidelines

23 Oct 2018 In News By

Update: Rebuttal to the 2018 ACG Crohn’s Disease Guidelines

In March 2018, the American College of Gastroenterology (ACG) released the 2018 Guidelines for the treatment of Crohn’s Disease (CD). Their conclusion, based on misinterpreted studies, that antimycobacterial therapy was not effective in inducing remission or mucosal healing in Crohn’s disease patients (page 498) prompted a response by some of the doctors in the Human Para community who have used AMAT with success. Read the letter that was published this week in the latest issue of Nature’s American Journal of Gastroenterology.

Berkeley Conference | Two Case Reports: Differing Antibiotic Regimens Resulting in Long-Term Mucosal Healing in Pediatric and Adult Crohn’s Patients

21 Oct 2018 In 2018 Berkeley By

Berkeley Conference | Two Case Reports: Differing Antibiotic Regimens Resulting in Long-Term Mucosal Healing in Pediatric and Adult Crohn’s Patients

In this presentation, Dr. William Chamberlin describes two Crohn’s disease patients who have found long term healing. The first, an adult patient, has altered the traditional antibiotic regimen to avoid side effects and keep the disease in deep remission. The second is a 10 year old pediatric patient who experienced remarkable healing on an antibiotic regimen.

Berkeley Conference | Qu Biologics’ Goal: Curing Crohn’s Disease by Restoring Innate Immunity

19 Oct 2018 In 2018 Berkeley By

Berkeley Conference | Qu Biologics’ Goal: Curing Crohn’s Disease by Restoring Innate Immunity

Dr. Hal Gunn is the founder and CEO of Qu Biologics, and has dedicated his professional life to understanding how to optimally support the body’s immune response to chronic disease. Dr. Gunn is recognized both nationally and internationally as a leader in the field of supportive cancer care, and is the founder and past-CEO of InspireHealth, Canada’s leading supportive oncology centres. Dr. Gunn obtained his Doctorate of Medicine from the University of British Columbia and remains on faculty at UBC’s School of Medicine. To learn more about QBECO and the study, please click on this link: https://www.quibd.com/

Berkeley Conference | Phase Assay Testing of Human PBMC’s

10 Oct 2018 In 2018 Berkeley By

Berkeley Conference | Phase Assay Testing of Human PBMC’s

Dr. Irene Grant is a Professor of Microbiology and Food Safety at Queen’s University in Belfast.  Her long time research interest has been Mycobacterium avium subsp. paratuberculosis, its heat resistance, presence in milk and dairy products, and methods for its accurate detection and enumeration. She has published extensively on this subject and is recognized as an international authority on this potentially foodborne and zoonotic bacterium. In this presentation, Dr. Grant reports on some preliminary findings of the Crohn’s/MAP Testing Study funded by Human Para, and describes her phage assay technique used for the detection of MAP.

Berkeley Conference | The Development and validation of a novel biomarker for diagnosis of Inflammatory Bowel Disease

07 Oct 2018 In 2018 Berkeley By

Berkeley Conference | The Development and validation of a novel biomarker for diagnosis of Inflammatory Bowel Disease

John Aitken is a free-lance microbiologist based out of Christchurch, New Zealand and the senior director of Otakaro Pathways, Ltd. Prior to his current position, he worked in medical microbiology for public and private providers for more than 40 years. His particular areas of interest are antimicrobial resistance and emerging bacterial infectious diseases. John is presently involved in research surrounding the relationship between immune diseases and the Mycobacterium species. Here, John discusses his latest research into mycobacterium species found in Crohn’s disease patients.